PMID- 35153138
OWN - NLM
STAT- MEDLINE
DCOM- 20220412
LR  - 20220517
IS  - 1499-3872 (Print)
VI  - 21
IP  - 2
DP  - 2022 Apr
TI  - Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: 
      A community-based study.
PG  - 154-161
LID - S1499-3872(22)00006-6 [pii]
LID - 10.1016/j.hbpd.2022.01.006 [doi]
AB  - BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) was recently proposed to be 
      renamed metabolic dysfunction-associated fatty liver disease (MAFLD) with the 
      diagnostic criteria revised. We investigated the similarities and differences in 
      the prevalence and clinical characteristics of MAFLD and NAFLD in Chinese adults. 
      METHODS: A cross-sectional study of 9980 Chinese individuals aged 40 years or 
      older was performed between 2011 and 2012 using randomized, stratified cluster 
      sampling in Shanghai, China. A detailed questionnaire and the results of 
      abdominal ultrasonography, a standardized 2-h 75-g oral glucose tolerance test 
      and blood biochemical examinations were collected. RESULTS: A total of 9927 
      subjects were included in this study. The prevalence of MAFLD (40.3%) was 
      significantly higher than that of NAFLD (36.9%) (P < 0.05). MAFLD was highly 
      prevalent in type 2 diabetes mellitus (T2DM) (53.8%), impaired fasting glucose 
      (35.7%) and impaired glucose tolerance (40.9%). High risk of advanced fibrosis 
      based on fibrosis-4 was highly prevalent (14.7%) in lean MAFLD with T2DM. Among 
      9927 subjects, 3481 (35.1%) fulfilled the diagnostic criteria for MAFLD and NAFLD 
      (MAFLD+NAFLD+), 521 (5.2%) MAFLD+NAFLD-, and 181 (1.8%) MAFLD-NAFLD+. The 
      MAFLD+NAFLD- group had more significant metabolic disorders than those in the 
      MAFLD+NAFLD+ group (all P < 0.05). Among MAFLD-NAFLD+ subjects, 82.9% had 
      metabolic disorders. CONCLUSIONS: The new definition of MAFLD may better reflect 
      the pathogenesis related to metabolism. Future research should focus on studying 
      the natural history, pathogenesis and treatment effectivity of the overlap and 
      non-overlap of NAFLD and MAFLD subjects.
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Zeng, Jing
AU  - Zeng J
AD  - Department of Gastroenterology, Xinhua Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai 200092, China.
FAU - Qin, Li
AU  - Qin L
AD  - Department of Endocrinology, Xinhua Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai 200092, China.
FAU - Jin, Qian
AU  - Jin Q
AD  - Department of Gastroenterology, Xinhua Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai 200092, China.
FAU - Yang, Rui-Xu
AU  - Yang RX
AD  - Department of Gastroenterology, Xinhua Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai 200092, China.
FAU - Ning, Guang
AU  - Ning G
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of 
      Endocrinology and Metabolism, Shanghai Clinical Center for Endocrine and 
      Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai 200127, China.
FAU - Su, Qing
AU  - Su Q
AD  - Department of Endocrinology, Xinhua Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai 200092, China.
FAU - Yang, Zhen
AU  - Yang Z
AD  - Department of Endocrinology, Xinhua Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai 200092, China. Electronic address: 
      yangzhen@xinhuamed.com.cn.
FAU - Fan, Jian-Gao
AU  - Fan JG
AD  - Department of Gastroenterology, Xinhua Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai 200092, China. Electronic address: 
      fanjiangao@xinhuamed.com.cn.
LA  - eng
PT  - Journal Article
DEP - 20220131
PL  - Singapore
TA  - Hepatobiliary Pancreat Dis Int
JT  - Hepatobiliary & pancreatic diseases international : HBPD INT
JID - 101151457
SB  - IM
CIN - Hepatobiliary Pancreat Dis Int. 2022 Apr;21(2):103-105. PMID: 35125337
MH  - Adult
MH  - China/epidemiology
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/complications/diagnosis/epidemiology
MH  - Fibrosis
MH  - Humans
MH  - *Metabolic Diseases/complications
MH  - *Non-alcoholic Fatty Liver Disease/complications/diagnostic imaging/epidemiology
MH  - Prevalence
OTO - NOTNLM
OT  - Metabolic dysfunction-associated fatty liver disease
OT  - Nonalcoholic fatty liver disease
OT  - Oral glucose tolerance test
OT  - Prevalence
EDAT- 2022/02/15 06:00
MHDA- 2022/04/13 06:00
CRDT- 2022/02/14 05:27
PHST- 2021/08/20 00:00 [received]
PHST- 2022/01/16 00:00 [accepted]
PHST- 2022/02/15 06:00 [pubmed]
PHST- 2022/04/13 06:00 [medline]
PHST- 2022/02/14 05:27 [entrez]
AID - S1499-3872(22)00006-6 [pii]
AID - 10.1016/j.hbpd.2022.01.006 [doi]
PST - ppublish
SO  - Hepatobiliary Pancreat Dis Int. 2022 Apr;21(2):154-161. doi: 
      10.1016/j.hbpd.2022.01.006. Epub 2022 Jan 31.